Trial of Mistletoe Extract in Patients With Advanced Solid Tumors
Status:
Active, not recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
This study will seek to determine the safety and toxicity profile as well as the maximum
tolerated dose of Helixor® M in patients with advanced solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins